Gen1119

Phase 1

Genmab

Gen1119 is one of 5 therapeutic programs targeting Solid Tumours. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Solid TumoursNot yet recruiting

Solid TumoursPhase 1

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Solid Tumours

#DrugCompanyPhaseTrials

Hernexeos

Boehringer Ingelheim

Phase 2

1 2

Imjudo

AstraZeneca

Phase 1

1 3

Brigimadlin

Boehringer Ingelheim

Phase 2

1 4

IV Durvalumab

AstraZeneca

Phase 1

1 5

Gen1119

Genmab

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Not yet recruiting

Solid Tumours

NCT07695831

Clinical

Trials by Indication[1]

Solid Tumours1 trial

First-In-Human, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of GEN1119 in Participants With Solid Tumors

Not yet recruiting· Genmab logo

Genmab·Phase 1·NCT07695831·112 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gen1119. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Gen1119. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Genmab company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Genmab

Gen1119

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Solid Tumours1 trial

References

Drug Info

Quick Facts

Related News